The dark side of a tumor suppressor: anti-apoptotic p53.
about
Phylostratigraphic tracking of cancer genes suggests a link to the emergence of multicellularity in metazoaSwitching Akt: from survival signaling to deadly responseOxidative stress and pulmonary fibrosisThe p53 pathway as a target in cancer therapeutics: obstacles and promiseCaught in the cross fire: p53 in inflammation.Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseasesAsbestos-induced lung diseases: an updateDifferential impact of tumor suppressor pathways on DNA damage response and therapy-induced transformation in a mouse primary cell modelSimultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML.Targeting p53 for Novel Anticancer Therapy.Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen.HOXA11 and MMP2 gene expression in uterosacral ligaments of women with pelvic organ prolapse.P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferationNF-κB regulates DNA double-strand break repair in conjunction with BRCA1-CtIP complexesA two-step mechanism for cell fate decision by coordination of nuclear and mitochondrial p53 activities.The antagonism between MCT-1 and p53 affects the tumorigenic outcomes.Genotoxic stress/p53-induced DNAJB9 inhibits the pro-apoptotic function of p53.Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.Identification of potential biomarkers for giant cell tumor of bone using comparative proteomics analysis.HOXA11 promotes fibroblast proliferation and regulates p53 in uterosacral ligamentsReciprocal influence of the p53 and the hypoxic pathwaysProteomic signatures associated with p53 mutational status in lung adenocarcinoma.Tumor protein p63/nuclear factor κB feedback loop in regulation of cell death.Translational approaches targeting the p53 pathway for anti-cancer therapy.MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathwaysProcessing Oscillatory Signals by Incoherent Feedforward Loops.Doxorubicin-induced necrosis is mediated by poly-(ADP-ribose) polymerase 1 (PARP1) but is independent of p53.The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells.Down-regulation of LATS kinases alters p53 to promote cell migration.Therapeutic targeting of the p53 pathway in cancer stem cells.Rap2b, a novel p53 target, regulates p53-mediated pro-survival functionTargeting cancer cells with the natural compound obtusaquinone.Molecular characterization of propionyllysines in non-histone proteins.miR-30e controls DNA damage-induced stress responses by modulating expression of the CDK inhibitor p21WAF1/CIP1 and caspase-3.Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.Highly activated p53 contributes to selectively increased apoptosis of latently HIV-1 infected cells upon treatment of anticancer drugs.p53 signaling is involved in leptin-induced growth of hepatic and breast cancer cells.Aging and cancer: converging routes to disease prevention.The p53 target Wig-1: a regulator of mRNA stability and stem cell fate?p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies.
P2860
Q21245316-55DC7A32-338A-4991-9CB8-475EFF326509Q24632379-7AF812DD-F197-4B9B-B3CD-BF90CF153845Q27024861-19D85749-275C-4B2E-B1BA-FCD147AF90A0Q27690770-3AE74D9B-E1A6-49CD-8F3C-51A6D92FB17AQ27692076-7665BF11-689C-4985-83CE-58FCBC115B15Q28389566-460EA97C-B971-44B7-960B-01EEFAA92DCCQ28393032-9581D6FE-D2CE-4EE1-8A97-4D06027698E8Q28472388-E0EF482A-334D-40A8-A574-50BD30610C52Q33597514-7EA3DB0D-7A4B-42DB-A8B0-4ED2CD750CD3Q33655329-5E808369-304D-4921-A904-8DC804568B76Q33751778-68B4B8E8-7EBB-4F6E-91D3-9A57F6A81D61Q33811824-F26F8968-ABFD-45B8-9BA2-B4F49B38FA36Q33913135-77404F62-4406-4D69-A852-49CA43BA9D9AQ34015940-0CD9D02F-875B-44AB-BBB2-7F8BF85E107BQ34297075-46D63184-0A79-4B84-8965-3F0E2EDABA91Q34481803-275B4C6D-3000-459D-A6BB-6ED1AF19521EQ34675243-8BDE9D93-C23D-46E9-8E18-307337EF09EFQ34709391-572F924B-80DC-4BA2-8292-8E61FAE66850Q34755599-A13A89EF-34C8-46F0-9701-CE2590AE5461Q35023773-0C7B3F93-460D-4503-B026-579A9FCE6C10Q35065006-5B927CC4-0506-42C3-B551-C54014BA33ADQ35492010-368770EB-ABEA-4466-BDB7-C0766FC7CBF4Q35604493-8DAF909E-716A-42CD-935B-3AF795F449CBQ35708113-47E230E1-4AE6-43EE-8E58-69E90640FD61Q35930474-69DFABB6-1C85-4835-92BD-51FA15295172Q36131481-3099E8EA-04AD-47A0-9549-A6B7530DADD9Q36237705-A50A0190-782F-401C-9A85-EA15D9FEA1DFQ36265434-61F67EEF-8B9D-46FB-AC72-5F6393D02409Q36406354-6BD9B798-6E49-4266-85AB-B05B1B48A347Q36833275-DE96ACB7-16D6-4362-8EC8-5FEBCF481205Q36906255-DA1816A6-9CD5-40F0-9EE8-D8CC649C4A0BQ36953575-2A4C38C9-09A6-42EB-B6D7-D6DF6C8BBCD3Q37051848-3E0EDF23-2D14-4A71-A0EA-4295E6F0B262Q37085916-19CB8FD3-9022-4759-A741-31E1F38B22B2Q37158722-CE72F603-8237-4220-B3CD-F759B4BEE78BQ37178474-C94586D6-A3A7-4DEE-BE8B-84CAA1EEC8B8Q37239773-165F7CA8-9C33-45B2-8591-C9F89CDDA5D3Q37579466-C84404EF-9859-49DF-A3D1-57BF9667A9CCQ37851826-85196962-AAD5-48F9-AC18-B8ED64D8C0B3Q37874926-AA5DA45F-AE32-49A0-B0F6-DA953EC32660
P2860
The dark side of a tumor suppressor: anti-apoptotic p53.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The dark side of a tumor suppressor: anti-apoptotic p53.
@en
The dark side of a tumor suppressor: anti-apoptotic p53.
@nl
type
label
The dark side of a tumor suppressor: anti-apoptotic p53.
@en
The dark side of a tumor suppressor: anti-apoptotic p53.
@nl
prefLabel
The dark side of a tumor suppressor: anti-apoptotic p53.
@en
The dark side of a tumor suppressor: anti-apoptotic p53.
@nl
P2093
P2860
P356
P1476
The dark side of a tumor suppressor: anti-apoptotic p53.
@en
P2093
K Schulze-Osthoff
R U Jänicke
P2860
P2888
P304
P356
10.1038/CDD.2008.33
P577
2008-03-21T00:00:00Z